Muscle Invasive Bladder Cancer (MIBC)
7
4
4
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
14%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (7)
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment
MRI-Guided Bladder Preservation Program For Patients With Muscle Invasive Bladder Cancer
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer